Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alloreactive NK cells
- Development stage
- Unknown
- Lead developer
- Sant’Orsola-Malpighi University Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Alloreactive NK cells (IRCCS Azienda Ospedaliero-Universitaria di Bologna) is an adoptive cell therapy being developed for the treatment of acute myeloid leukemia (AML). The therapy utilizes highly purified CD56+CD3- natural killer (NK) cells harvested from haploidentical donors who exhibit a KIR-ligand mismatch with the recipient. This mismatch prevents the inhibition of NK cells by the recipient's self-HLA molecules, thereby triggering potent graft-versus-leukemia (GvL) activity. The cells are administered as a consolidation strategy for adult AML patients in complete remission who are not candidates for allogeneic stem cell transplantation. The treatment protocol includes lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by the NK cell infusion and subsequent interleukin-2 (IL-2) administration to support cell expansion and persistence.
- Other names
- donor-derived CD56+CD3- NK cellshaploidentical KIR-ligand-mismatched NK cellsalloreactive NK cell infusion
02
Targets
KIR–HLA interface (KIR–HLA class I interface)
Beyond the preview
Go deeper on alloreactive NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alloreactive NK cells.